NO751769L - - Google Patents
Info
- Publication number
- NO751769L NO751769L NO751769A NO751769A NO751769L NO 751769 L NO751769 L NO 751769L NO 751769 A NO751769 A NO 751769A NO 751769 A NO751769 A NO 751769A NO 751769 L NO751769 L NO 751769L
- Authority
- NO
- Norway
- Prior art keywords
- capa
- gel
- fraction
- subjected
- temperature
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 69
- 238000000034 method Methods 0.000 claims description 56
- 239000000499 gel Substances 0.000 claims description 55
- 239000000427 antigen Substances 0.000 claims description 54
- 102000036639 antigens Human genes 0.000 claims description 53
- 108091007433 antigens Proteins 0.000 claims description 53
- 239000000243 solution Substances 0.000 claims description 43
- 201000011510 cancer Diseases 0.000 claims description 39
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 102000009027 Albumins Human genes 0.000 claims description 16
- 108010088751 Albumins Proteins 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 15
- 230000007935 neutral effect Effects 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- 238000010828 elution Methods 0.000 claims description 12
- 238000005119 centrifugation Methods 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 11
- 239000002808 molecular sieve Substances 0.000 claims description 11
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 9
- 230000007717 exclusion Effects 0.000 claims description 9
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 238000005194 fractionation Methods 0.000 claims description 8
- 238000002523 gelfiltration Methods 0.000 claims description 8
- 229920002401 polyacrylamide Polymers 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 150000002500 ions Chemical class 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 229920005654 Sephadex Polymers 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 6
- 230000003053 immunization Effects 0.000 claims description 6
- 238000002649 immunization Methods 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000011543 agarose gel Substances 0.000 claims description 5
- 239000000356 contaminant Substances 0.000 claims description 5
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 230000000717 retained effect Effects 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000003929 acidic solution Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000010668 complexation reaction Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 229910000831 Steel Inorganic materials 0.000 claims 2
- 230000008014 freezing Effects 0.000 claims 2
- 238000007710 freezing Methods 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 2
- 238000010422 painting Methods 0.000 claims 2
- 239000010959 steel Substances 0.000 claims 2
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 238000012936 correction and preventive action Methods 0.000 description 89
- 210000001519 tissue Anatomy 0.000 description 37
- 239000000843 powder Substances 0.000 description 19
- 210000000601 blood cell Anatomy 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000000890 antigenic effect Effects 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 210000002826 placenta Anatomy 0.000 description 10
- 239000007853 buffer solution Substances 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 235000019253 formic acid Nutrition 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000035931 haemagglutination Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 239000013049 sediment Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 101710180448 CD-NTase-associated protein 7 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 101500025736 Drosophila melanogaster CAP-1 Proteins 0.000 description 1
- 241000698776 Duma Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- 208000008636 Neoplastic Processes Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000980746 Traverhyphes indicator Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000005357 flat glass Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO751769A NO751769L (cs) | 1972-07-10 | 1975-05-16 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27027372A | 1972-07-10 | 1972-07-10 | |
| NO2807/73A NO146338C (no) | 1972-07-10 | 1973-07-09 | Preparat for anvendelse ved diagnostisering av cancer |
| NO751769A NO751769L (cs) | 1972-07-10 | 1975-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO751769L true NO751769L (cs) | 1974-01-11 |
Family
ID=27352618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO751769A NO751769L (cs) | 1972-07-10 | 1975-05-16 |
Country Status (1)
| Country | Link |
|---|---|
| NO (1) | NO751769L (cs) |
-
1975
- 1975-05-16 NO NO751769A patent/NO751769L/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4160018A (en) | Stabilized cancer associated polypeptide antigen and preparation thereof | |
| US3960827A (en) | Cancer associated polypeptide antigen, process for its preparation, process for preparing antibodies, process of cancer diagnosis and composition useful as an immunizing agent | |
| Wang | Filamin, a new high-molecular-weight protein found in smooth muscle and nonmuscle cells. Purification and properties of chicken gizzard filamin | |
| Lüning et al. | Biochemical properties of tissue polypeptide antigen | |
| Pras et al. | Isolation of a non-collagenous reticulin component and its primary characterization | |
| US5866690A (en) | Detection of malignant tumor cells | |
| JPH0822876B2 (ja) | ペプチドホルモンカルジオジラチン及びその製造法 | |
| US4486538A (en) | Detection of malignant tumor cells | |
| US4211766A (en) | Cancer associated polypeptide antigen compositions | |
| Springer et al. | Blood group Tn-active macromolecules from human carcinomas and erythrocytes: characterization of and specific reactivity with mono-and poly-clonal anti-Tn antibodies induced by various immunogens | |
| Schmid et al. | Characterization of the proteins of certain postmortem human synovial fluids | |
| Ratcliffe et al. | Identification and partial characterization of parathyroid hormone-related protein in human and bovine milk | |
| Cathcart et al. | Immunogenicity of amyloid | |
| JP2710645B2 (ja) | ｓｎＲＮＰ−Ａ抗原及びそのフラグメント | |
| CN102336828B (zh) | 一种多发性骨髓瘤特异性蛋白及其专用检测试剂盒 | |
| JPH0354679B2 (cs) | ||
| CN107298697B (zh) | 一种人pd-l1蛋白y123位点磷酸化抗体及其制备方法和应用 | |
| Lapresle et al. | Immunogenicity of a fragment of human serum albumin | |
| NO751769L (cs) | ||
| Chen et al. | Separation and characterization of a porcine‐specific thermostable muscle protein from cooked pork | |
| Garmaise et al. | Immunological detection of antigen (s) associated with rat colon carcinoma | |
| JPS5817168B2 (ja) | ガンカンレンポリペプチドコウゲン オヨビ ソノセイゾウナラビニリヨウ | |
| Shochat et al. | Characterization of colon-specific antigen-p and isolation of immunologically active tryptic peptides. | |
| Guarneri et al. | A study of diazepam binding inhibitor (DBI) processing products in human cerebrospinal fluid and in postmortem human brain | |
| Adelmann | The structural basis of cell-mediated immunological reactions of collagen: Recognition by the cutaneous delayed hypersensitivity reaction in guinea-pigs of conformational alternations of rat and calf skin collagen |